Ralimetinib

Overview

Ralimetinib is an ATP-competitive p38α and p38β MAPK inhibitor with an IC 50 of 5.3 nmol/L against human p38α and an IC 50 of 3.2 nmol/L against human p38β . Ralimetinib slows tumor growth in preclinical in vivo cancer models, exhibits oral bioavailability in mice, and achieves sustained target inhibition for 4 to 8 h. Ralimetinib is applicable for research on melanoma, non-small cell lung cancer , ovarian cancer , glioma, multiple myeloma, breast cancer , renal cancer , and head and neck squamous cell carcinoma.

Application

Products | Products > Disease Areas > Breast Cancer | Products > Disease Areas > Non-Small Cell Lung Cancer | Products > Disease Areas > Metastatic Breast Cancer | Products > Disease Areas > Cancer | Products > Disease Areas > Respiratory Disease | Products > Disease Areas > Lung Cancer | Products > Disease Areas > Respiratory Cancer | Products > Signaling Pathways > MAPK/ERK Pathway | Products > Signaling Pathways > Autophagy | Products > Research Areas > Cancer | Products > Research Areas > Cancer > Cancer Targeted Therapy | Products > Research Areas > Cancer > Cancer Metabolism and Metastasis | Products > Signaling Pathways > p38 MAPK | Products > Signaling Pathways > Autophagy

Product Information

• Catalog No.: HY-13241A
• CAS No.: 862505-00-8
• Molecular Formula: C24H29FN6
• Molecular Weight: 420.53
• Purity: 98.58%
• Storage: Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month
• Solubility: ≥ 2.5 mg/mL (5.94 mM); Clear solution
• Availability: In-stock

Source

Original product source